Role of ADGRG1/GPR56 in Tumor Progression.
GPR56
adhesion GPCR
ligand
signaling
tumorigenesis
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
29 11 2021
29 11 2021
Historique:
received:
01
11
2021
accepted:
23
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
19
1
2022
Statut:
epublish
Résumé
Cellular communication plays a critical role in diverse aspects of tumorigenesis including tumor cell growth/death, adhesion/detachment, migration/invasion, angiogenesis, and metastasis. G protein-coupled receptors (GPCRs) which constitute the largest group of cell surface receptors are known to play fundamental roles in all these processes. When considering the importance of GPCRs in tumorigenesis, the adhesion GPCRs (aGPCRs) are unique due to their hybrid structural organization of a long extracellular cell-adhesive domain and a seven-transmembrane signaling domain. Indeed, aGPCRs have been increasingly shown to be associated with tumor development by participating in tumor cell interaction and signaling. ADGRG1/GPR56, a representative tumor-associated aGPCR, is recognized as a potential biomarker/prognostic factor of specific cancer types with both tumor-suppressive and tumor-promoting functions. We summarize herein the latest findings of the role of ADGRG1/GPR56 in tumor progression.
Identifiants
pubmed: 34943858
pii: cells10123352
doi: 10.3390/cells10123352
pmc: PMC8699533
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Ligands
0
Receptors, G-Protein-Coupled
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Lett. 2006 Feb 28;233(2):265-70
pubmed: 15916848
Dev Dyn. 2010 Dec;239(12):3358-67
pubmed: 20981830
Mol Cell. 2021 Mar 4;81(5):905-921.e5
pubmed: 33497605
Cell Rep. 2017 Nov 21;21(8):2183-2197
pubmed: 29166609
PLoS One. 2012;7(1):e29818
pubmed: 22238662
Tohoku J Exp Med. 2016;239(3):203-11
pubmed: 27396430
Pharmacol Rev. 2015;67(2):338-67
pubmed: 25713288
Oncotarget. 2017 Jun 20;8(25):40606-40619
pubmed: 28380450
J Endocrinol. 2020 Feb;244(2):395-413
pubmed: 31829965
Cell. 2019 May 16;177(5):1217-1231.e18
pubmed: 31006530
Cancer Med. 2019 Apr;8(4):1771-1778
pubmed: 30848055
Adv Exp Med Biol. 2010;706:98-108
pubmed: 21618829
J Cell Sci. 2016 Jun 1;129(11):2156-69
pubmed: 27068534
Front Pharmacol. 2018 May 22;9:431
pubmed: 29872392
Trends Pharmacol Sci. 2011 Aug;32(8):443-50
pubmed: 21612832
Cell Mol Life Sci. 2018 Nov;75(21):4007-4019
pubmed: 29855662
J Clin Endocrinol Metab. 2016 Dec;101(12):4637-4645
pubmed: 27636017
Trends Endocrinol Metab. 2006 Mar;17(2):48-54
pubmed: 16460957
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Cancer Invest. 2011 Jan;29(1):42-8
pubmed: 20874003
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Sci Rep. 2019 Jul 30;9(1):11036
pubmed: 31363148
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15756-61
pubmed: 25336758
Onco Targets Ther. 2016 Jul 05;9:4105-12
pubmed: 27462165
Handb Exp Pharmacol. 2016;234:127-146
pubmed: 27832487
J Invest Dermatol. 2017 Mar;137(3):727-736
pubmed: 27818281
PLoS One. 2014 Jun 20;9(6):e100043
pubmed: 24949629
Nat Rev Cancer. 2007 Feb;7(2):79-94
pubmed: 17251915
Int J Mol Sci. 2016 Aug 12;17(8):
pubmed: 27529230
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6194-9
pubmed: 25918380
Haematologica. 2020 Jan 09;105(10):e507
pubmed: 33054093
Trends Biochem Sci. 2008 Oct;33(10):491-500
pubmed: 18789697
Oncogene. 2005 Mar 3;24(10):1673-82
pubmed: 15674329
Mol Pharmacol. 2012 Nov;82(5):777-83
pubmed: 22821233
Handb Exp Pharmacol. 2016;234:369-396
pubmed: 27832497
J Biol Chem. 2016 Feb 12;291(7):3385-94
pubmed: 26710850
Oncol Rep. 2018 Oct;40(4):1885-1896
pubmed: 30066935
ACS Pharmacol Transl Sci. 2020 Jan 13;3(1):29-42
pubmed: 32259086
J Neurosci. 2009 Jun 10;29(23):7439-49
pubmed: 19515912
Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118563
pubmed: 31666191
Int Immunol. 2010 Feb;22(2):91-100
pubmed: 20008459
Nat Commun. 2015 Jan 21;6:6121
pubmed: 25607655
Ann N Y Acad Sci. 2012 Dec;1276:1-25
pubmed: 23215895
Biol Pharm Bull. 2015;38(4):594-600
pubmed: 25832639
FEBS Lett. 1999 Mar 12;446(2-3):292-8
pubmed: 10100861
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Neoplasma. 2017;64(1):32-39
pubmed: 27881002
Stem Cell Res. 2015 May;14(3):307-22
pubmed: 25840412
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:429-449
pubmed: 28968187
Biochem Biophys Res Commun. 2015 Aug 28;464(3):679-84
pubmed: 26116532
Blood Adv. 2021 Feb 9;5(3):829-842
pubmed: 33560396
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9023-8
pubmed: 16757564
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Blood. 2016 Apr 21;127(16):2018-27
pubmed: 26834243
Trends Pharmacol Sci. 2001 Jul;22(7):368-76
pubmed: 11431032
Neuron. 2016 Sep 21;91(6):1292-1304
pubmed: 27657451
Angew Chem Int Ed Engl. 2013 Jun 17;52(25):6366-78
pubmed: 23650015
FEBS J. 2013 Dec;280(23):6097-113
pubmed: 24102982
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12925-30
pubmed: 21768377
Neoplasma. 2021 May;68(3):580-589
pubmed: 33618521
Cancer Res. 2011 Aug 15;71(16):5558-68
pubmed: 21724588
Cancer Sci. 2021 Dec;112(12):4883-4893
pubmed: 34632664
EMBO J. 2012 Mar 21;31(6):1364-78
pubmed: 22333914
Mol Pharmacol. 2018 May;93(5):477-488
pubmed: 29476042
Leukemia. 2016 Aug;30(8):1734-41
pubmed: 27063597
Sci Rep. 2020 Oct 9;10(1):16912
pubmed: 33037308
Nat Commun. 2020 Apr 2;11(1):1635
pubmed: 32242018
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28275-28286
pubmed: 33097663
Future Oncol. 2012 Apr;8(4):431-40
pubmed: 22515446
Trends Pharmacol Sci. 2013 Aug;34(8):470-8
pubmed: 23850273
J Biol Chem. 2008 May 23;283(21):14469-78
pubmed: 18378689
PLoS One. 2013 Jul 09;8(7):e68781
pubmed: 23874761
Mol Cancer Ther. 2007 Jun;6(6):1840-50
pubmed: 17575113
Cell Rep. 2015 Feb 17;10(6):1021
pubmed: 30849857
J Exp Med. 2018 Mar 5;215(3):941-961
pubmed: 29367382
EMBO J. 2020 Aug 17;39(16):e104136
pubmed: 32452062
J Biol Chem. 2019 Dec 13;294(50):19246-19254
pubmed: 31628191
Nature. 2009 May 21;459(7245):356-63
pubmed: 19458711
Mol Pharmacol. 2003 Jun;63(6):1256-72
pubmed: 12761335
Elife. 2018 May 29;7:
pubmed: 29809138
Cancer Cell. 2017 Oct 9;32(4):506-519.e5
pubmed: 29017060
Chang Gung Med J. 2012 Jan-Feb;35(1):15-27
pubmed: 22483424
Science. 2004 Mar 26;303(5666):2033-6
pubmed: 15044805
Cancer Res. 2014 Feb 15;74(4):1022-31
pubmed: 24356421
Cell Rep. 2016 May 24;15(8):1757-70
pubmed: 27184850
Sci Rep. 2018 Sep 13;8(1):13741
pubmed: 30214063
Leukemia. 2013 Aug;27(8):1637-49
pubmed: 23478665
Genomics. 1999 Feb 1;55(3):296-305
pubmed: 10049584
Mol Cancer Res. 2019 Nov;17(11):2196-2207
pubmed: 31444231
Mol Biol Cell. 2004 May;15(5):2375-87
pubmed: 15004227
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10095-10100
pubmed: 28874577
Nat Commun. 2015 Jan 21;6:6122
pubmed: 25607772
Biomed J. 2021 Oct;44(5):534-547
pubmed: 34654683
J Leukoc Biol. 2011 Oct;90(4):735-40
pubmed: 21724806
J Cancer Res Clin Oncol. 2010 Jan;136(1):47-53
pubmed: 19572147
Front Oncol. 2018 Aug 08;8:304
pubmed: 30135857
J Biol Chem. 2011 Aug 19;286(33):28914-28921
pubmed: 21708946
J Biol Chem. 2004 Jul 23;279(30):31823-32
pubmed: 15150276
Mol Pharmacol. 2016 Sep;90(3):214-24
pubmed: 27338081
Science. 2014 Feb 14;343(6172):764-8
pubmed: 24531968
Clin Exp Metastasis. 2010 Apr;27(4):241-9
pubmed: 20333450
Mol Pharmacol. 2015 Sep;88(3):617-23
pubmed: 25956432
J Biol Chem. 2021 Jan-Jun;296:100261
pubmed: 33837725
J Biol Chem. 2017 Jun 9;292(23):9711-9720
pubmed: 28424266